Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Medical Device Business Strategies

Restructuring Roche's R&D: An Interview with Lee Babiss

Executive Summary

Even though Roche has been the single most successful investment in Big Pharma--because Roche has been the single most successful investor in Big Pharma--productivity over the past few years was slowed by leadership bottlenecks, misalignment among functions, and roadblocks to creativity. Roche's brand-new research boss, Lee Babiss, says a new decentralized structure and a more aggressive out-partnering strategy is designed to address the issues, manage risk, and spur post-2015 growth
Table

View full table

Related Content

Scrip Pink Sheet In Vivo In Vivo In Vivo In Vivo In Vivo In Vivo In Vivo In Vivo

Topics

Related Companies

Related Deals

Tags:
BioPharmaceutical Medical Device Business Strategies
UsernamePublicRestriction

Register

IV003011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By